A combination of increasing prices and sector-wide "shrinkflation" has led to more Americans bypassing their favorite — ...

I went all out—£2000 worth of LEGO sets in one trip! Here's what I bought. #LEGOBigHaul #LEGOStore #UltimateHaul ...

I created a battle between a water dragon and a village of vikings! The dragon sent a powerful jet of water that destroyed ...

Dario Perkins, an economist at macro research firm TS Lombard, interpreted that the market would welcome Trump's (reluctant) vote of confidence, but the damage he has done to the Fed's independence is ...

Zepbound (tirzepatide) is a once-a-week injectable weight-loss medication. It helps reduce your appetite by influencing two hormones: glucagon-like peptide-1 (GLP-1) and glucose-dependent ...

No, this isn’t some late-night infomercial fantasy — it’s the reality of Zepbound, and it’s changing everything about how we approach weight loss. While you’ve been cycling through diets ...

Eli Lilly is suing four telemedicine companies selling compounded versions of its blockbuster obesity drug Zepbound and its diabetes treatment Mounjaro, escalating its battle against unauthorized ...

This is partly thanks to Zepbound, a weight loss medicine that's already generating more than $1 billion in quarterly sales, although it was approved only in late 2023. Zepbound's prospects still ...

There are other reasons to invest in the pharmaceutical leader. Zepbound's prospects still look bright, but some recent developments point to another weight loss drug that could become yet another ...

Lilly sells tirzepatide as Mounjaro for type 2 diabetes and Zepbound for obesity. In the complaints, Lilly alleges that the telemedicine companies are marketing tirzepatide mixed with substances ...

IQVIA’s Doug Long offers a lay of the land, including trends and developing issues that are shaping the current market.

Eli Lilly is suing four telehealth companies selling compounded versions of the pharmaceutical giant's weight loss drug Zepbound and its diabetes treatment Mounjaro, the company's latest attempt ...